India is set to get its first approved dengue vaccine, Qdenga, with Dr. Reddy’s Laboratories entering into an agreement with Takeda Pharmaceuticals to promote and distribute the vaccine in the country’s private market.
The vaccine is expected to become available in the first half of 2027, subject to completion of the required regulatory processes. The companies have not yet announced its price.
Vaccine Approved for People Aged 4–60
India’s Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation for Qdenga in July 2026 for individuals aged 4 to 60 years.
Qdenga is a live-attenuated tetravalent dengue vaccine designed to provide protection against all four dengue virus serotypes.
Dr. Reddy’s to Handle Private-Market Distribution
Under the agreement, Dr. Reddy’s will have exclusive rights to promote and distribute Qdenga in India’s private market for paediatric and adult vaccination. Takeda will retain commercialisation rights in the public market and will manufacture and import the vaccine.
As per Hindustan Times, the partnership will also focus on healthcare-professional engagement, disease awareness and promotion of dengue prevention.
Addressing India’s Dengue Burden
Dengue remains a significant public-health challenge in India, with all four dengue virus serotypes circulating across multiple regions. The companies said the collaboration aims to improve awareness and access to dengue vaccination while supporting broader efforts to address the disease burden.
Public Programme Inclusion
Takeda has said that inclusion of Qdenga in India’s public immunisation programme remains a long-term objective. For now, the planned rollout will focus on the private market once the vaccine becomes commercially available.
Further details on pricing and availability are expected closer to the launch.